C9062 — Injection, daratumumab 10 mg and hyaluronidase-fihj
C9062 is a HCPCS Level II code for injection, daratumumab 10 mg and hyaluronidase-fihj. It belongs to the Outpatient Prospective Payment System section. It was terminated on December 31, 2020 and is not valid on new claims.
This code has been terminated
CMS terminated C9062 on December 31, 2020. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9062
- Long descriptor
- Injection, daratumumab 10 mg and hyaluronidase-fihj
- Short descriptor
- Daratumumab hyaluronidase
- Added
- October 1, 2020
- Terminated
- December 31, 2020
- BETOS
- O1D
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9062
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9062 is not quite right, the correct code is very often within a few positions of it.
- C9054Injection, lefamulin (xenleta), 1 mgterminated
- C9055Injection, brexanolone, 1mgterminated
- C9056Injection, givosiran, 0.5 mgterminated
- C9057Injection, cetirizine hydrochloride, 1 mgterminated
- C9058Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo) 0.5 mgterminated
- C9059Injection, meloxicam, 1 mgterminated
- C9060Fluoroestradiol f18, diagnostic, 1 mciterminated
- C9061Injection, teprotumumab-trbw, 10 mgterminated
- C9063Injection, eptinezumab-jjmr, 1 mgterminated
- C9064Mitomycin pyelocalyceal instillation, 1 mgterminated
- C9065Injection, romidepsin, non-lyophilized (e.g. liquid), 1mgterminated
- C9066Injection, sacituzumab govitecan-hziy, 2.5 mgterminated
- C9067Gallium ga-68, dotatoc, diagnostic, 0.01 mci
- C9068Copper cu-64, dotatate, diagnostic, 1 millicurieterminated
- C9069Injection, belantamab mafodontin-blmf, 0.5 mgterminated
- C9070Injection, tafasitamab-cxix, 2 mgterminated
Questions about C9062
What is HCPCS code C9062?
C9062 is a HCPCS Level II code for injection, daratumumab 10 mg and hyaluronidase-fihj. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9062?
The CMS HCPCS file marks C9062 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9062 still valid?
No. C9062 was terminated on December 31, 2020 and should not be used on new claims.